NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Profitability
This table compares NeuroBo Pharmaceuticals and PTC Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroBo Pharmaceuticals | N/A | -60.64% | -43.74% |
| PTC Therapeutics | -75.49% | N/A | -39.69% |
Analyst Recommendations
This is a summary of current recommendations and price targets for NeuroBo Pharmaceuticals and PTC Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroBo Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| PTC Therapeutics | 1 | 6 | 5 | 0 | 2.33 |
Institutional and Insider Ownership
4.8% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 0.8% of NeuroBo Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
NeuroBo Pharmaceuticals has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
Valuation and Earnings
This table compares NeuroBo Pharmaceuticals and PTC Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroBo Pharmaceuticals | N/A | N/A | -$13.97 million | N/A | N/A |
| PTC Therapeutics | $698.80 million | 4.42 | -$559.02 million | ($8.42) | -4.87 |
NeuroBo Pharmaceuticals has higher earnings, but lower revenue than PTC Therapeutics.
Summary
PTC Therapeutics beats NeuroBo Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
